Articles related to IMMUNOTHERAPY

The FDA advisory committee’s decision highlights the complexities of perioperative treatment in NSCLC and the need for more precise efficacy data to guide clinical decision-making.

The addition of blinatumomab to consolidation chemotherapy in adults with MRD-negative B-cell precursor ALL demonstrated a significant improvement in overall survival. At 3 years, the overall survival rate was 85% in the blinatumomab group compared to 68% in the chemotherapy-only group.

Dupilumab significantly induced histologic remission in 68% of children with eosinophilic esophagitis compared to 3% in the placebo group, according to a phase 3 trial.

Teclistamab, a BCMA bispecific antibody, demonstrates a promising 63% overall response rate in heavily pretreated R/R MM patients, with manageable toxicity compared to CAR T-cell therapy.

In a phase 2 study of patients with locally advanced mismatch repair–deficient colon cancer, treatment with neoadjuvant nivolumab plus ipilimumab resulted in a 98% pathological response rate and a 68% pathological complete response rate, with no recurrence of disease observed over a median follow-up of 26 months.

A phase 3 trial comparing neoadjuvant ipilimumab plus nivolumab followed by surgery to adjuvant nivolumab alone in resectable stage III melanoma patients found a significantly higher event-free survival rate in the neoadjuvant group. This suggests that pre-surgical immunotherapy could lead to better patient outcomes.